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Background:  Percutaneous ventricular assist device (pVAD) support in cardiogenic shock (CS) patients has been associated with lower 
costs, shorter lengths of stay (LOS) and reduced readmissions when compared to extracorporeal membrane oxygenation (ECMO) support. 
The hospital cost and utilization profile of an episode of care (EOC, combining index hospitalization and readmissions) as well as gender-
specific differences have not been explored.
methods:  A retrospective comparison of the EOC for CS patients treated by two alternative cardiac support devices during calendar years 
2011-2012 was captured via the Medicare Inpatient Standard Analytic File (100% census file); 649 eligible cases (pVAD M=304, F=213, 
ECMO M=76, F=56) with 90 days of follow-up care were included. 
results:  At 30 and 90 days following the index hospitalization, EOC costs were significantly lower at 30 and 90 days for patients treated 
with pVAD (30 day: pVAD = $115,541, ECMO = $275,897, p<.001; 90 day: pVAD = $127,817, ECMO = $310,005, p<.001). EOC LOS was 
significantly lower (55%) for patients treated with pVAD compared to ECMO (30-day LOS: pVAD = 21 days, ECMO = 47 days, p<.001; 
90-day LOS: pVAD = 26 days, ECMO = 58 days, p<.001). Readmission rates at 30 and 90 days were also 24% to 27% lower for patients 
treated with pVAD (30 Day: pVAD = 25.9%, ECMO = 34.1%, p=.064; 90 Day: pVAD = 38.7%, ECMO = 53.0%, p=.004). Reductions in EOC 
cost, LOS and readmission rates followed similar trends once stratified by gender. For females, 90-day readmissions remained significantly 
lower for pVAD versus ECMO (p=.004), but not for males (p=.100). Forthcoming analyses will describe additional differences including the 
cost of post-acute care (PAC).
conclusion:  In CS patients, pVADs are associated with reduced EOC cost, LOS and readmissions. Moreover, preliminary evidence 
suggests that the consistent performance of pVADs across gender may help offset the heightened readmission risk experienced by female 
patients. Increased adoption of pVAD for treating patients with CS increases value and quality of care for patients, providers and payers. 
Additional investigation will utilize a cardiogenic shock patient cohort with medical management alone.
